Core Points - Apollomics Inc. has successfully appealed a delisting notice from Nasdaq and will continue to be listed on the Nasdaq Stock Market [1] - The company is focused on developing therapies for resistant and refractory cancers, with its lead candidate being vebreltinib (APL-101), a selective c-Met inhibitor [2] Group 1 - Apollomics Inc. is a late-stage clinical biopharmaceutical company based in California, dedicated to developing various candidate oncology drugs [1] - The Nasdaq listing qualification department has determined that Apollomics meets the requirements for continued listing, leading to the cancellation of the scheduled appeal hearing [1] - The company's securities will continue to trade on the Nasdaq Stock Market [1] Group 2 - Apollomics is currently conducting Phase II multi-cohort clinical trials for vebreltinib, targeting non-small cell lung cancer and other advanced tumors with c-Met gene alterations [2] - The company aims to explore and develop cancer therapies that leverage the human immune system and target specific molecular pathways [2]
Apollomics 宣布听证会取消后继续在 Nasdaq 股票市场上市